Global Traumatic Brain Injury Therapeutics Market is segmented By Route of Administration (Oral, Parenteral), By Drug Type (Anticonvulsants, Anti-anxiety agents, Anticoagulants, Analgesics, Others), By Distribution Channel (Hospital Pharmacies, Retail Drug Stores, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Market Overview
Global Traumatic Brain Injury Therapeutics Market is estimated to grow at a CAGR of 4.9% during the forecast period 2024-2031.
Traumatic brain injury usually results from a violent blow or jolt to the head or body. An object that goes through brain tissue, such as a bullet or shattered piece of skull, also can cause traumatic brain injury. Mild traumatic brain injury may affect brain cells temporarily. More serious traumatic brain injury can result in bruising, torn tissues, bleeding and other physical damage to the brain. These injuries can result in long-term complications or death. Treatments for TBI are based on the severity of the injury.
Market Summary
| Metrics | Details |
| Market CAGR | 4.9% |
| Segments Covered | By Route of Administration, By Drug Type, By Distribution Channel and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For More Insights Insights Request Free Sample
Market Dynamics
The increasing prevalence of patients with brain injuries, rising cases of car accidents and injuries cases. Furthermore, numerous technological innovations and advancements, extensive research and development activities, and a large volume of clinical trials are being conducted to develop traumatic brain injuries. These factors drive the market in the forecast period.
The increasing clinical trials of drugs for treating traumatic brain injury are expected to drive market growth.
SanBio's SB623 demonstrated safe and productive results in Phase 2 clinical trial in which moderate to severe TBI patients with chronic motor deficits received MSCs intracranially. Six months after MSC implantation, participants receiving MSCs improved their motor skills by 8.3 points on average compared to the control group, which improved by 2.3 points on average. SanBio is preparing to submit a Biologics License Application for SB623 in Japan and advance its global development program.
Additionally, PNT001, developed by Pinteon Therapeutics, is the only monoclonal antibody in clinical development for severe TBI. PNT001 is a tau antibody that targets cis-pT231 Tau, a toxic neuroepitope that phosphorylates and accumulates after TBI11 (Table 1). Pinteon received $3 million from Advanced Technology International, a nonprofit contractor of the United States Department of Defense, in June 2021 to conduct Phase 1 trials in TBI and announced plans to begin a Phase 1b study of PNT001 in Alzheimer's disease patients by the end of 2021. Furthermore, in July 2021, Pinteon extended a multiyear manufacturing collaboration with Lonza, most likely in preparation for the upcoming clinical studies. Thus, from the above factors, the market is expected to drive in the forecast period.
The high cost of traumatic brain injury treatment is expected to hamper the market growth.
The cost of a traumatic brain injury is frequently subjective. Healthcare costs vary by municipality, and each injury presents a unique set of challenges. For instance, the National Institutes of Health's National Library of Medicine published cost-related findings. After reviewing over 2,300 sources, the report found that in-hospital healthcare costs ranged from $2,130 to $401,808 per victim. The study also revealed that in-hospital costs varied according to the severity of the TBI and the length of stay.
Moreover, the Centres for Disease Control and Prevention (CDC) agreed that TBI costs are high and uneven. The CDC also estimated that the total annual national cost of non-fatal TBI conditions is more than $40.6 billion; one-time emergency room treatment costs average more than $6,620; and 11 days of lost wages average more than $1,600. Thus, from the above factors, the market is expected to hamper in the forecast period.
COVID-19 Impact on Traumatic Brain Injury Therapeutics Market
The coronavirus has moderately impacted the traumatic brain injury therapeutics market. Traumatic brain injury (TBI) has been referred to as the "silent epidemic," but given its substantial and recurring impact on global health, it should be renamed to the "silent pandemic." Although the incidence of traumatic brain injury (TBI) has decreased since the start of the coronavirus disease 2019 (COVID-19) pandemic, and the severe acute respiratory syndrome coronavirus two is still evolving, the number of TBI cases has increased significantly in multiple countries. However, TBI mortality rates in low- to middle-income countries increased during the COVID-19 pandemic. During the pandemic, the rate of assault as a cause of TBI also increased. The pandemic has greatly affected TBI biomedical research; experimental and clinical studies have slowed or stopped, and resources have been reallocated, resulting in a "lost year" for the TBI field. Thus, from the above factors, the market got affected. However, the situation is expected to improve gradually in the forecast period.
Market Segmentation Analysis
Stimulants segment is expected to hold the largest market share in traumatic brain injury therapeutics market
The stimulants segment accounted for the largest market share in 2021. Stimulants are drugs used to improve cognitive function following a traumatic brain injury. Ritalin (also known as methylphenidate) increases frontal lobe activity in people who struggle with self-regulation and self-control. Ritalin is primarily used to treat ADHD but can also improve alertness following a brain injury. Methylphenidate also improves attention and focus in TBI survivors, according to research.
Moreover, Modafinil and Adderall are two other psychostimulants that doctors may prescribe for traumatic brain injury recovery. These can help boost alertness, increase dopamine levels in the brain, and combat extreme cognitive fatigue. While psychostimulants can help improve cognitive function after a brain injury, survivors should also engage in cognitive therapy to address the underlying cause and increase their chances of recovery. Thus, from the above factors, the market segment accounted for the largest market share in the forecast period.
Market Geographical Share
North America region holds the largest market share in the global traumatic brain injury therapeutics market
North America region accounted for the largest market share in 2021. Owing to the increase in the number of traumatic brain injury cases, the increasing clinical trials by the market players, rising investment by the researchers for combating TBI, and the acquisition by the market players are the factors to drive the market in the forecast period. For instance, On May 3, 2021, Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative brain injuries, announced today the completion of its Series A financing, which raised $6.0 million. Astrocyte is moving forward with its lead development candidate AST-004, based on technology licensed from The University of Texas Health Science Center in San Antonio. This drug will address an unmet need for a drug that can reduce brain injury caused by stroke, traumatic brain injury (TBI), concussion, and other neurodegenerative conditions.
In addition, in August 2021, Arkansas Children’s Hospital agreed to acquire TRIUX neo for functional brain imaging. This will help in the detection capability when diagnosing patients across a wide spectrum, including epilepsy, brain tumors, traumatic brain injury, post-traumatic stress disorder, and autism. Thus, from the above factors, the North American region accounted for the largest market share in the forecast period.
Market Companies
Major key players in the traumatic brain injury therapeutics market are Lupin, Novartis, Teva Pharmaceutical, Sanofi, F. Hoffmann-La Roche Ltd, Invagen Pharms, Pfizer, Arbor Pharmaceuticals, Mylan N.V and Baxter.
On 14 April 2021, Moleac announced the approval of the US Food and Drug Administration (FDA) of an investigational new drug (IND) application for MLC1501 in traumatic brain injury (TBI).
Pfizer Inc:
Overview:
Pfizer Inc. is an American multinational pharmaceutical company. The company develops and manufactures medicines and vaccines for various medical disciplines, including immunology, oncology, cardiology, endocrinology, neurology and other therapeutic areas. It sells its prescription pharmaceutical products to wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. Pfizer Limited has over 150 products across 15 therapeutic areas. It sells its vaccines to the federal government and the Centers for Disease Control and Prevention in the United States (CDC).
Product Portfolio:
NEURONTIN (gabapentin) capsules: Gabapentin is in a class of medications called anticonvulsants. Gabapentin treats seizures by decreasing abnormal excitement in the brain. Gabapentin relieves the pain of PHN by changing the way the body senses pain.
The global traumatic brain injury therapeutics market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.
